Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence s...

por Cohen, Stanley, Genovese, Mark C, Choy, Ernest, Perez-Ruiz, Fernando, Matsumoto, Alan, Pavelka, Karel, Pablos, Jose L, Rizzo, Warren, Hrycaj, Pawel, Zhang, Nan, Shergy, William, Kaur, Primal
Publicado 2017

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

por Westhovens, Rene, Robles, Manuel, Ximenes, Antonio Carlos, Wollenhaupt, Jurgen, Durez, Patrick, Gomez-Reino, Juan, Grassi, Walter, Haraoui, Boulos, Shergy, William, Park, Sung-Hwan, Genant, Harry, Peterfy, Charles, Becker, Jean-Claude, Murthy, Bindu
Publicado 2015